Lumateperone

Atypical antipsychotic medication

Lumateperone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Lumateperone, marketed under the brand name Caplyta, is an atypical antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It was developed by Intra-Cellular Therapies and received approval from the United States Food and Drug Administration (FDA) in December 2019.

Pharmacology

Lumateperone acts as a serotonin receptor antagonist, dopamine receptor modulator, and glutamate receptor modulator. It has a unique mechanism of action compared to other antipsychotics, targeting multiple neurotransmitter systems in the brain.

Mechanism of Action

Lumateperone's antipsychotic effects are believed to be mediated through its activity at several receptor sites:

• Serotonin 5-HT_2A receptor antagonism: This is a common target for atypical antipsychotics, which helps in reducing psychotic symptoms.
• Dopamine D₂ receptor partial agonism: Lumateperone modulates dopamine activity, which is crucial in managing symptoms of schizophrenia.
• Glutamate receptor modulation: It affects the glutamatergic system, which may contribute to its efficacy and side effect profile.

Clinical Use

Lumateperone is indicated for the treatment of schizophrenia in adults. It is also approved for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults.

Dosage and Administration

Lumateperone is administered orally, typically once daily with or without food. The recommended dose for schizophrenia is 42 mg per day. For bipolar depression, the dosage may vary based on clinical response and tolerability.

Side Effects

Common side effects of lumateperone include somnolence, dry mouth, dizziness, and fatigue. It is generally well-tolerated, with a lower incidence of metabolic side effects compared to other atypical antipsychotics.

Warnings and Precautions

Lumateperone carries a warning for increased mortality in elderly patients with dementia-related psychosis, similar to other antipsychotics. It should be used with caution in patients with a history of cardiovascular disease, seizures, or conditions that predispose them to hypotension.

Development and Approval

Lumateperone was developed by Intra-Cellular Therapies, a biopharmaceutical company focused on the development of novel drugs for the treatment of neuropsychiatric and neurological disorders. The FDA approved lumateperone for the treatment of schizophrenia in December 2019, and for bipolar depression in December 2021.

Related pages

• Schizophrenia
• Bipolar disorder
• Atypical antipsychotic
• Dopamine receptor
• Serotonin receptor